BerGenBio ASA (BGBIO.OL)
- Previous Close
1.7820 - Open
1.7980 - Bid 1.7040 x --
- Ask 1.8000 x --
- Day's Range
1.7000 - 1.7980 - 52 Week Range
1.4498 - 16.0000 - Volume
80,074 - Avg. Volume
756,850 - Market Cap (intraday)
68.402M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9500 - Earnings Date May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.90
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
www.bergenbio.comRecent News: BGBIO.OL
View MorePerformance Overview: BGBIO.OL
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGBIO.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGBIO.OL
View MoreValuation Measures
Market Cap
68.40M
Enterprise Value
-70.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
72.80
Price/Book (mrq)
0.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.26%
Return on Equity (ttm)
-111.35%
Revenue (ttm)
848k
Net Income Avi to Common (ttm)
-139.28M
Diluted EPS (ttm)
-3.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
140.16M
Total Debt/Equity (mrq)
1.03%
Levered Free Cash Flow (ttm)
-99.87M